SCHEMBL475058

SCHEMBL475058

CC(C)(O)/C=C/c1ccc(C(F)(F)F)cc1C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.46
HPGD P15428 3/20 0.46
KDM4E B2RXH2 2/20 0.46
HSD17B10 Q99714 2/20 0.46
USP2 O75604 1/20 0.44
CYP2C19 P33261 1/20 0.44
CES2 O00748 2/20 0.41
SORT1 Q99523 9/20 0.41
LIPC P11150 1/20 0.40
LIPG Q9Y5X9 1/20 0.40
TAS2R14 Q9NYV8 1/20 0.40
GRIK1 P39086 1/20 0.39
MEN1 O00255 1/20 0.39
CYP1A2 P05177 1/20 0.39
ALOX12 P18054 1/20 0.39
KMT2A Q03164 1/20 0.39
KDM1A O60341 1/20 0.39
RXRA P19793 1/20 0.38
RXRB P28702 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL475060 1.00 ALDH1A1 (0.46) ALDH1A1HPGDKDM4EHSD17B10USP2
SCHEMBL78139 0.78 ALDH1A1 (0.54) ALDH1A1HPGDKDM4EHSD17B10USP2
SCHEMBL19679619 0.76 ALDH1A1 (0.49) ALDH1A1HPGDKDM4EHSD17B10USP2
SCHEMBL460066 0.71 KDM4E (0.69) ALDH1A1HPGDKDM4EHSD17B10USP2
SCHEMBL9541475 0.71 ALDH1A1 (0.59) ALDH1A1HPGDKDM4EHSD17B10USP2
SCHEMBL710431 0.71 TAS2R14 (0.59) ALDH1A1HPGDKDM4EHSD17B10USP2
SCHEMBL22265173 0.70 ALDH1A1 (0.57) ALDH1A1HPGDKDM4EHSD17B10USP2
SCHEMBL168327 0.69 KDM4E (0.61) ALDH1A1HPGDKDM4EHSD17B10USP2
SCHEMBL29243250 0.69 ALDH1A1 (0.56) ALDH1A1HPGDKDM4EHSD17B10USP2
SCHEMBL43771 0.69 ALDH1A1 (0.59) ALDH1A1HPGDKDM4EHSD17B10USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2411370-B1 COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS ABBVIE INC (US) 2015-04-22 EP disclosed
US-8288428-B2 Compounds as cannabinoid receptor ligands ABBOTT LABORATORIES (US) 2012-10-16 US disclosed
EP-2411370-A1 COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS Abbott Laboratories (US) 2012-02-01 EP disclosed
US-20100249087-A1 COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2010-09-30 US disclosed
WO-2010111573-A1 COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249087-A1 COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS CNR1, CNR2, GPR18 ALDH1A1 825/4885HPGD 1548/4885KDM4E 2286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.